title: Dominant expression of multidrug resistance in intraspecific murine lymphoma hybrid cells.
abstract: Cultured P388/VCR mouse lymphoma cells resistant to vincristine (VCR) and to 5-bromodeoxyuridine (BUdR) and deficient in thymidine kinase (TK-) were fused with P388/DAG cells resistant to 1.2:5,6-dianhydrogalactitol (DAG), an anticancer alkylating agent, and to 6-thioguanine (6-TG) and deficient in hypoxanthine phosphoribosyl-transferase (HPRT-). The hybrid cells expressed multidrug resistance (MDR), i.e., resistance to VCR and cross-resistance to Adriamycin (ADM) and actinomycin D (Act. D), in a dominant manner. The presence of glycoprotein p170, the MDR gene product, was detected in the hybrid cells. Resistance to DAG was also expressed dominantly, whereas cross-resistance to dibromodulcitol (DBD), a chemically related anticancer drug, was slight.
authors.affiliation: Research Center of Oncology, National Institute of Oncology, Budapest, Hungary.
authors.forename: I
authors.initials: I
authors.lastname: Pályi
authors.forename: G
authors.initials: G
authors.lastname: Turi
authors.forename: L
authors.initials: L
authors.lastname: Hullán
authors.forename: K
authors.initials: K
authors.lastname: Szikla
authors.forename: M
authors.initials: M
authors.lastname: Bak
mesh_terms: D020168:ATP Binding Cassette Transporter, Subfamily B, Member 1; D000818:Animals; D000970:Antineoplastic Agents / Q000494:pharmacology*; D001973:Bromodeoxyuridine / Q000494:pharmacology; D002352:Carrier Proteins / Q000032:analysis / Q000235:genetics*; D002459:Cell Fusion; D002470:Cell Survival / Q000187:drug effects; D003609:Dactinomycin / Q000494:pharmacology; D003961:Dianhydrogalactitol / Q000494:pharmacology; D004305:Dose-Response Relationship, Drug; D004317:Doxorubicin / Q000494:pharmacology; D004351:Drug Resistance / Q000235:genetics*; D015870:Gene Expression; D006822:Hybrid Cells / Q000187:drug effects / Q000378:metabolism*; D007041:Hypoxanthine Phosphoribosyltransferase / Q000172:deficiency; D007124:Immunoenzyme Techniques; D007621:Karyotyping; D008223:Lymphoma / Q000188:drug therapy* / Q000378:metabolism; D008562:Membrane Glycoproteins / Q000032:analysis / Q000235:genetics*; D051379:Mice; D010641:Phenotype; D013866:Thioguanine / Q000494:pharmacology; D013937:Thymidine Kinase / Q000172:deficiency; D014750:Vincristine / Q000494:pharmacology
chemical_list: D020168:ATP Binding Cassette Transporter, Subfamily B, Member 1; D000970:Antineoplastic Agents; D002352:Carrier Proteins; D008562:Membrane Glycoproteins; D003609:Dactinomycin; D003961:Dianhydrogalactitol; D014750:Vincristine; D004317:Doxorubicin; D007041:Hypoxanthine Phosphoribosyltransferase; D013937:Thymidine Kinase; D013866:Thioguanine; D001973:Bromodeoxyuridine